FdaApplication
NDA 021466
Identifiers
- fda_app_no: NDA021466
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER |
| application_type | NDA |
Revenue by product
VFEND
| Period | Revenue |
|---|---|
| Q4 2023 | $34.0M |
| Q3 2023 | $46.0M |
| Q2 2023 | $56.0M |
| Q1 2023 | $51.0M |
| Q4 2022 | $54.0M |
| Q3 2022 | $51.0M |
| Q2 2022 | $54.0M |
| Q1 2022 | $65.0M |
| Q4 2021 | $63.0M |
| Q3 2021 | $51.0M |
| Q2 2021 | $72.0M |
| Q1 2021 | $80.0M |
| Q4 2020 | $69.0M |
| Q3 2020 | $52.0M |
| Q2 2020 | $75.0M |
| Q1 2020 | $74.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VFEND | VORICONAZOLE | 200MG | Tablet;Oral |
| VFEND | VORICONAZOLE | 200MG/VIAL | Injectable;Iv (Infusion) |
| VFEND | VORICONAZOLE | 50MG | Tablet;Oral |
3 products